Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 1150


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Diagnostic Substances
  • Disease
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1150

License Grant
The Licensor granted an exclusive, worldwide license to the relevant Diagnostic Technology.

Diagnostic Technology  means any information, inventions, and discoveries made, conceived, derived, or otherwise reduced to practice by Licensor related to the Field.

License Property
U.S. Patent No. 5,516,638 Immunoassays for the Detection of Antibodies to Chlamydia Trachomatis in the Urine.
Field of Use
Field of Use means any urine-based medical diagnostic test.

IPSCIO Record ID: 2386

License Grant
The Licensor, an individual, and the Licensee desire to hereby amend and restate the Original Agreement in its entirety to clarify certain rights and obligations of the parties from and after March 1, 1997.
License Property
Licensor owns U.S. Patent No. 5,516,638 Immunoassays for the Detection of Antibodies to Chlamydia Trachomatis in the Urine.  Issued May 14, 1996.
Field of Use
The Field means any urine-based medical diagnostic test.

IPSCIO Record ID: 1800

License Grant
The University grants to IMMTECH a worldwide, exclusive, and non-assignable License to use the Invention and Patent Rights (07/765,169 ) of Immunoassay for Identifying Alcoholics and Monitoring Alcohol Consumption (NIT 9134); Licensed Product coveted hereby and to make, have made, use and sell the products in the Field of Quantitative Diagnostics.  Quantitative Diagnostics shall mean the use of immunoassays that yield a quantitative answer and are generally performed via enzyme-linked antibody methodology.
Field of Use
Field of Use  shall mean the exclusive use of the invention and patent rights for quantitative diagnostics.

IPSCIO Record ID: 26289

License Grant
The Licensor hereby grants to the Israeli Company, a non-exclusive, worldwide license to make, have made, market, distribute (directly or by means of local distributors), and Sell Licensed Products. Technology, generally characterized as Diagnostic Methods for Chlamydia Pneumoniae, Tech I.D. #07-86-34,  is covered by certain patent and know-how rights.
License Property
The Technology is comprised of three methods and associated materials for the detection and/or diagnosis of Chlamydia Pneumoniae, namely Monoclonal antibody-based antigen detection, serological antibody detection, and nucleic acid probe based detection.
Field of Use
“Field of Use”, as used herein, shall mean those portions of the Technology directly pertaining to methods and materials for the serological detection of antibodies, and their use by the Licensee to develop arid market assays.  The Field of Use expressly excludes the nucleic acid probe and Monoclonal antibody – based detection materials and methods of detecting Chlamydia Pneumoniae and expressly excludes the right to sell the diagnostic test results.

IPSCIO Record ID: 10350

License Grant
The Developer, government organization, of rapid saliva testing products, has enhanced its exclusive, worldwide license for the flow immunosensor technology (FIT).

Licensor grants to an exclusive right and license to practice the licensed invention throughout the United States and in the licensed territory in the field of saliva based human diagnostics and urine based testing for drugs of abuse and urine based testing for Methadone, Benzodiazapines Barbituates, Propoxyphene, Tricyclic Antidepressants and Anabolic Steroids.

License Property
FIT is a kinetic immunoassay that provides rapid diagnostic testing results onsite.

Licensor has an assignment of title to the invention disclosed and claimed in U.S. Patent Application Serial No. 07/486,024, and U.S. Patent No. 5,183,740 for Flow Immunosensor Method and Apparatus.

Field of Use
The agreement expands the field of use from drugs of abuse and anabolic steroids on urine samples to include all possible diagnostic uses for saliva.

IPSCIO Record ID: 626

License Grant
Licensor  is willing to grant to Licensee a royalty-bearing, worldwide non-exclusive  license under the Licensed Patents.
License Property
Licensed Products shall mean Urine-based  immunoassays and serum, plasma, oral fluid or whole Blood-based  Immunoassays (i) which have a composition containing an HIV-2 antigen,  (ii) which are manufactured, used or sold by Licensee or its Affiliate and are capable of detecting HIV 1/2 antibodies and/or  antigen only on Licensee's Point of Care Rapid Test platform.

Licensed Patents
HIV-2 (Foundational)
EP 0239 425; EP 0 320 495; EP 284 383; EP 283 327
US 4,839,288; US 5,030,718; US 5,055,391; US 5,066,782;
US 5,268,265; US 5,364,933; US 5,051,496; US 5,770,703; US 5,830,641; US 5,079,342; US 6,048,685; US 6,162,439; US 6,261,762; US 6,265,149; US 6,322,964; US 5,306,614;
US 5,580,739; US 6,518,015

IPSCIO Record ID: 6345

License Grant
The Company grants an exclusive, worldwide, royalty-bearing License, with the right to subLicense, to make, have made, use, sell and import Licensed Products, which includes finished products used for the detection of the Company’s proprietary prostate cancer biomarkers in both urine and biopsied prostate tissue for differentiating clinically significant prostate cancer from other prostate conditions, and to use Patent Rights and Know-How covering the prostate cancer biomarkers.
License Property
Licensed Product(s) shall mean finished products consisting of one or more nucleic acid detection reagents for the assay of one or more Prostate Marker(s) for use in the Field, the manufacture, use, sale or importation of which, but for the rights granted herein, would infringe a Valid Claim within Patent Rights.

Method of Identifying Patterns in Biological Systems and Uses Thereof

Biomarkers Upregulated in Prostate Cancer

Biomarkers Overexpressed in Prostate Cancer

Methods for Screening, Predicting and Monitoring Prostate Cancer

Methods for Screening, Predicting and Monitoring Prostate Cancer

Field of Use
Field shall mean the use of a molecular diagnostic assay using the Licensed Prostate Markers in in vitro diagnostics relating to prostate cancer, including the detection of the presence or risk of prostate cancer, or the selection of therapy, or in a Research Application related to prostate cancer.

IPSCIO Record ID: 2819

License Grant
Licensor hereby grants to Licensee,  a non-exclusive, non-transferable (except to an affiliate) right and license under the Licensed Patents, without the right to sublicense, to make, have made for its own use and sale, use, offer for sale and import Product and to practice the methods claimed in the Licensed Patents in connection with such Product, all of the foregoing limited expressly to the field of all human in vitro manually formatted immunodiagnostic assays.
License Property
Conceive 1-Step Pregnancy
QuickVue One Step hCG-Urine
QuickVue One Step hCG-Combo
Q Test Pregnancy
Conceive 1-Step Ovulation Predictor
QuickVue Chlamydia
QuickVue In-Line One-Step Strep A
QuickVue Flex Strep A
QuickVue H.  Pylori

Licensed Patents shall mean United States Letters Patent No.  5,591,645.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.